Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial

Enriqueta Felip大牛学者,Egbert F Smit大牛学者,Miguel A Molina-Vila,Urania Dafni,Bartomeu Massuti,Thierry Berghmans,Filippo de Marinis,Francesco Passiglia,Anne-Marie C Dingemans,Manuel Cobo,Santiago Viteri,Christian Britschgi,Sinead Cuffe,Mariano Provencio,Sabine Merkelbach-Bruse, Charitini Andriakopoulou, Roswitha Kammler,Barbara Ruepp,Heidi Roschitzki-Voser,Solange Peters大牛学者,Jürgen Wolf,Rolf Stahel

Lung Cancer（2022）

引用 2|浏览14

暂无评分

摘要

•Single-arm trial exploring the alectinib activity in RET-rearranged advanced NSCLC.•14 patients were enrolled until the premature accrual closure.•No objective response (CR or PR) was observed.•Disease control at 24 weeks achieved by three patients; median PFS = 3.7 months.•Erythema multiforme led to treatment discontinuation in three cases.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络